MENU

ALMS Alumis Inc. Forecast, Technical & Fundamental Analysis

Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases... Show more

ALMS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
View a ticker or compare two or three
ALMS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Details
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GDT34.370.64
+1.91%
WisdomTree Efficient TIPS Plus Gold Fund
PXE34.090.35
+1.04%
Invesco Energy Exploration & Prod ETF
AOR69.270.56
+0.82%
iShares Core 60/40 Balanced Allc ETF
SPXU37.400.19
+0.51%
ProShares UltraPro Short S&P500
TSMX86.65N/A
N/A
Direxion Daily TSM Bull 2X Shares

ALMS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ALMS has been loosely correlated with ZNTL. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ALMS jumps, then ZNTL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALMS
1D Price
Change %
ALMS100%
-0.53%
ZNTL - ALMS
34%
Loosely correlated
+2.41%
ARVN - ALMS
32%
Poorly correlated
+2.32%
MRNA - ALMS
32%
Poorly correlated
+10.01%
DRUG - ALMS
31%
Poorly correlated
+1.59%
VRDN - ALMS
29%
Poorly correlated
+4.98%
More
Alumis (ALMS) stock Forecast, Price Targets and Analysts Predictions - Tickeron.com